Huan Qiao
Overview
Explore the profile of Huan Qiao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Qiao H, Zienkiewicz J, Hawiger J
Skin Health Dis
. 2024 Jun;
4(3):e356.
PMID: 38846687
Background: In the two common inflammatory skin diseases, Atopic Dermatitis (AD) and Psoriasis (Ps), keratinocytes (KCs) respond to immune insults through activation of proinflammatory transcription factors (TFs) and their translocation...
2.
Pan D, Qiao H, Wang H, Wu S, Wang J, Wang C, et al.
Nutr Metab Cardiovasc Dis
. 2024 Mar;
34(5):1274-1282.
PMID: 38494369
Background And Aims: To examine the association of serum 25-hydroxyvitamin D [25(OH)D] with all-cause mortality and disease-specific mortality in patients with hypertension. Methods And Results: This cohort study included US...
3.
Dong X, Qiao H, Zhu Q, Yao Y
Math Biosci Eng
. 2023 Sep;
20(8):14046-14060.
PMID: 37679124
In this paper, we study the output tracking control problem based on the event-triggered mechanism for cascade switched nonlinear systems. Firstly, an integral controller based on event-triggered conditions is designed,...
4.
Qiao H, Zienkiewicz J, Liu Y, Hawiger J
Front Immunol
. 2023 Aug;
14:1221102.
PMID: 37638006
The steady rise of sepsis globally has reached almost 49 million cases in 2017, and 11 million sepsis-related deaths. The genomic response to sepsis comprising multi-system stage of raging microbial...
5.
Liu Y, Zienkiewicz J, Qiao H, Gibson-Corley K, Boyd K, Veach R, et al.
Sci Rep
. 2022 Nov;
12(1):18891.
PMID: 36344555
Atopic Dermatitis (AD) or eczema, a recurrent allergic inflammation of the skin, afflicts 10-20% of children and 5% adults of all racial and ethnic groups globally. We report a new...
6.
Li E, Yan R, Yan K, Zhang R, Zhang Q, Zou P, et al.
Front Immunol
. 2022 Oct;
13:987344.
PMID: 36211348
Spinal cord injury refers to damage to the spinal cord due to trauma, disease, or degeneration; and the number of new cases is increasing yearly. Significant cellular changes are known...
7.
Sato H, Kubota D, Qiao H, Jungbluth A, Rekhtman N, Schoenfeld A, et al.
JCO Precis Oncol
. 2022 Aug;
6:e2200088.
PMID: 35952318
Purpose: The identification of novel oncogenic driver alterations and novel mechanisms of acquired resistance (AR) is the key for further development of personalized therapy. The current study investigates the potential...
8.
Qiao H, Sun X, Wu X, Li G, Wang Z, Li D
Biol Open
. 2019 Oct;
8(11).
PMID: 31649117
Microbes in soil can degrade insoluble inorganic and organic phosphorus, which are components of the soil phosphorus cycle and play an important role in plant growth. is a pioneer tree...
9.
Horn L, Whisenant J, Wakelee H, Reckamp K, Qiao H, Leal T, et al.
J Thorac Oncol
. 2019 Aug;
14(11):1901-1911.
PMID: 31446141
Introduction: Despite initial effectiveness of ALK receptor tyrosine kinase inhibitors (TKIs) in patients with ALK+ NSCLC, therapeutic resistance will ultimately develop. Serial tracking of genetic alterations detected in circulating tumor...
10.
Brown B, Zhang Y, Westover D, Yan Y, Qiao H, Huang V, et al.
Clin Cancer Res
. 2019 Feb;
25(11):3341-3351.
PMID: 30796031
Purpose: The third-generation EGFR inhibitor, osimertinib, is the first mutant-selective inhibitor that has received regulatory approval for the treatment of patients with -mutant lung cancer. Despite the development of highly...